RUES1
RUESe001-A
General#
Cell Line |
|
| hPSCreg Name | RUESe001-A |
| Alternative name(s) |
RUES1
|
| Cell line type | Human embryonic stem cell (hESC) |
| Last update | 22nd May 2019 |
| User feedback | |
Provider |
|
| Generator |
The Rockefeller University (RUES)
Contact:
Laboratory of Molecular Embryology |
| Owner | Wyss Institute for Biologically Inspired Engineering at Harvard University |
| Distributors | |
| Derivation country | United States |
External Databases |
|
| Cellosaurus | CVCL_B809 |
| BioSamples | SAMEA104387754 |
| NIHhESC | NIHhESC-09-0012 |
| CLO | CLO_0101496 |
General Information |
|
| Publications |
|
| Projects | |
| * Is the cell line readily obtainable for third parties? |
Yes Clinical: allowed
Commercial: allowed
|
Donor Information#
General Donor Information |
|
| Sex | female |
| Ethnicity | unknown |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Disease associated phenotypes | no phenotypes |
| Family history | NA |
| Is the medical history available upon request? | no |
| Is clinical information available? | no |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
No
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
|
Ethics#
| Was the embryo established purely for research purposes? | No |
| Have both parents consented to the use of the embryo for ESC derivation? | Yes |
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Alternatives to consent are available? | Yes |
| Alternatives to consent | |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Clinical Research and Development Services Corp. |
| Approval number | 03-06-01 |
hESC Derivation#
| Date of derivation | 2004-08-30 |
| Embryo stage | Blastula with ICM and Trophoblast |
| Supernumerary embryos from IVF treatment? |
Yes
|
| PGD Embryo? |
No |
| ZP removal technique | Enzymatic |
| Cell isolation | Immunosurgery |
Culture Conditions#
| Feeder cells |
MEF Cellfinder Ont Id: EFO_0004040 |
|||||||||
| Medium |
Other medium:
Base medium: Knockout-DMEM
Main protein source: Knock-out serum replacement Serum concentration: 20 % Supplements
|
Characterisation#
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
|
|||
| Alkaline Phosphatase |
Yes |
|
||||
| SSEA-3 |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
Differentiation Potency
Genotyping#
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46XY
Passage number: 15
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
|
Login to share your feedback, experiences or results with the research community.